Updated Jul 16, 2026
Simpson Curran has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $417K.
Curran Simpson is the Chief Executive Officer of REGENXBIO Inc., a biotechnology company focused on gene therapy for various genetic diseases. Under his leadership, the company has advanced its platform targeting metabolic, neurodegenerative, and retinal diseases.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | RGNX | REGENXBIO Inc. | F — Tax withholding / forfeiture | 6.8K | $13.09 | $89K |
| 2026-07-06 | RGNX | REGENXBIO Inc. | A — Grant or award | 1.5K | $10.18 | $15K |
| 2026-07-06 | RGNX | REGENXBIO Inc. | A — Grant or award | 951 | $7.00 | $7K |
| 2025-10-09 | RGNX | REGENXBIO Inc. | S — Open-market sale | 20.8K | $12.62 | $263K |
| 2025-09-29 | RGNX | REGENXBIO Inc. | S — Open-market sale | 7.6K | $10.03 | $76K |
| 2025-09-10 | RGNX | REGENXBIO Inc. | S — Open-market sale | 7.7K | $10.02 | $77K |
| 2025-07-01 | RGNX | REGENXBIO Inc. | F — Tax withholding / forfeiture | 4.7K | $8.23 | $39K |
Curran Simpson is the Chief Executive Officer of REGENXBIO Inc., a biotechnology company focused on gene therapy for various genetic diseases. Under his leadership, the company has advanced its platform targeting metabolic, neurodegenerative, and retinal diseases.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($417K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Simpson Curran profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.